

CITATION REPORT

List of articles citing

Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008

DOI: 10.2165/11593210-0000000000-000000

Clinical Pharmacokinetics, 2011, 50, 627-35.

Source: <https://exaly.com/paper-pdf/50147604/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
123	Journal Watch. 2011 , 25, 415-424		
122	Pharmacometrics for regulatory decision making: status and perspective. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 625-6	6.2	17
121	Personalized medicine policy challenges: measuring clinical utility at point of care. 2012 , 12, 289-95		15
120	A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. 2012 , 55, 562-7		17
119	CPT: Pharmacometrics and Systems Pharmacology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012 , 1, e8	4.5	53
118	Basic concepts in population modeling, simulation, and model-based drug development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012 , 1, e6	4.5	233
117	White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e40	4.5	10
116	Improper selection of a pre-specified primary dose-response analysis delays regulatory drug approval. 2013 , 15, 407-14		3
115	Model-based drug development: a rational approach to efficiently accelerate drug development. 2013 , 93, 502-14		165
114	The utility of modeling and simulation in drug development and regulatory review. 2013 , 102, 2912-23		157
113	Is this the dose for you?: the role of modeling. 2013 , 93, 159-62		8
112	Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects. 2013 , 57, 897-902		10
111	Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. 2013 , 93, 515-25		31
110	Use of a biomarker in exposure-response analysis to support dose selection for fingolimod. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e67	4.5	7
109	Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. 2013 , 125, 53-61		27
108	Life Cycle Modeling and Simulation: Current Practice and Future Impact on Health Care Innovation and Delivery. 2013 , 47, 175-182		1
107	Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium. 2013 , 74, 112-126		9

106	Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study. 2013 , 53, 1112-20		
105	Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. 2013 , 6, 159-70		15
104	Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e51	4.5	100
103	Regulatory modeling and simulation moves into the next gear in europe. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e32	4.5	2
102	Modeling and simulation in clinical pharmacology and dose finding. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e29	4.5	7
101	Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects. 2013 , 57, 903-7		7
100	Optimization of mycophenolic acid therapy using clinical pharmacometrics. 2014 , 29, 4-11		16
99	The evolution of the regulatory framework for antibacterial agents. 2014 , 1323, 11-21		28
98	Building bridges and providing transparency to the hepatitis C virus drug approval process. 2014 , 147, 1201-3		
97	Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. 2014 , 6, 239-53		25
96	Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysis. 2014 , 55, e134-8		3
95	Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. 2014 , 73, 127-39		26
94	Use of predictive models in CNS diseases. 2014 , 14, 23-9		3
93	Should pharmacometrics be training the next R&D president?. 2014 , 95, 579-80		2
92	The Practice of Pharmacometrics. 2014 , 1-8		2
91	Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 565-75	4.5	45
90	A proposal for scientific framework enabling specific population drug dosing recommendations. 2015 , 55, 1073-8		34
89	Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1337-49	3.8	17

88	Catalyzing the Critical Path Initiative: FDA progress in drug development activities. 2015 , 97, 221-33		25
87	Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. 2015 , 4, 187-98		34
86	Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1183-204	6.2	70
85	[Rational estimation of drug dosage through pharmacometric modeling: The case of a long-acting depot antipsychotic]. 2015 , 41, 159-67		2
84	Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. 2015 , 17, 853-70		46
83	Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures. 2015 , 55, 81-92		7
82	Modeling and Simulation Applications in Drug Development Process. 2016 , 55-65		
81	Role of Pharmacometrics in Drug Development in the Pediatric Population. 2016 , 47, 89-104		1
80	Utility of Exposure-Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease. 2016 , 56, 1035-8		2
79	Translational Modeling of Antibacterial Agents. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016 , 371-402	0.5	
78	Using Systems Pharmacology to Advance Oncology Drug Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016 , 421-463	0.5	1
77	Perspectives in regulatory science: translational and clinical pharmacology. 2016 , 21-22, 67-73		2
76	Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist. 2016 , 72, 533-43		12
75	The promises of quantitative systems pharmacology modelling for drug development. 2016 , 14, 363-370		51
74	Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go. 2016 , 12, 1143-56		9
73	Communicating to Influence Drug Development and Regulatory Decisions: A Tutorial. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 163-72	4.5	2
72	Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. 2016 , 39, 213-23		21
71	Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. 2016 , 2, 171-177		14

70	Food and Drug Administration Drug Approval Process: A History and Overview. 2016 , 51, 1-11	16
69	Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 93-122	4.5 176
68	Recent developments in using mechanistic cardiac modelling for drug safety evaluation. 2016 , 21, 924-38	42
67	A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application. 2017 , 7, 39494	11
66	Phxnlme: An R package that facilitates pharmacometric workflow of Phoenix NLME analyses. 2017 , 140, 121-129	1
65	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. 2017 , 19, 607-618	4
64	Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. 2017 , 31, 558-566	7
63	Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference. 2017 , 27, 554-567	2
62	Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations. 2017 , 106, 950-960	10
61	Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. 2017 , 23, 6421-6429	4
60	Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. 2017 , 19, 1523-1535	1
59	The implications of model-informed drug discovery and development for tuberculosis. 2017 , 22, 481-486	10
58	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. 2017 , 10, 443-454	34
57	Humans Vary, So Cardiac Models Should Account for That Too!. 2017 , 8, 700	3
56	An automated sampling importance resampling procedure for estimating parameter uncertainty. 2017 , 44, 509-520	43
55	Parameter estimation for sigmoid E models in exposure-response relationship. 2017 , 25, 74-84	5
54	Regulatory Perspectives in Pharmacometric Models of Osteoporosis. 2018 , 58, 572-585	7
53	Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations. 2018 , 20, 64	2

52	Avibactam Pharmacokinetic/Pharmacodynamic Targets. 2018 , 62,	40
51	Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development. 2018 , 11, 123-146	21
50	New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. 2018 , 33, 61-64	5
49	Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate. 2018 , 138, 203-211	4
48	Quantitative systems pharmacology: Extending the envelope through systems engineering. 2018 , 42, 3-34	2
47	Orphan drug development: the increasing role of clinical pharmacology. 2019 , 46, 395-409	8
46	Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling. 2019 , 59 Suppl 1, S104-S111	10
45	Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. 2019 , 12, 2835-2850	6
44	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharmaceutical Statistics</i> 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873. 2019 , 18, 278-281	
43	A Holistic and Integrative Approach for Advancing Model-Informed Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 9-11	4.5 21
42	Model Informed Drug Development and Regulation in China: Challenges and Opportunities. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 59-61	4.5 5
41	Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic Proteins. 2019 , 108, 73-77	8
40	Population pharmacokinetics of vactosertib, a new TGF- β receptor type I inhibitor, in patients with advanced solid tumors. 2020 , 85, 173-183	7
39	The Case for an Unblinded Modeler in Early Clinical Development. 2020 , 60, 369-377	
38	Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy. 2020 , 11, 1041	3
37	Mathematical Modeling for the Physiological and Clinical Investigation of Glucose Homeostasis and Diabetes. 2020 , 11, 575789	4
36	Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. 2020 , 28, 1217-1227	1
35	External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients. 2020 , 76, 1281-1289	5

34	Time to Expect More From Pharmacometrics. 2020 , 108, 1129-1131		2
33	Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. 2020 , 11, 316		3
32	Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. 2020 , 55, 1154-1160		3
31	The ADME Encyclopedia. 2021 , 1-7		
30	Physiologically-based pharmacokinetic modeling after drug inhalation. 2021 , 319-358		1
29	How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug. 2021 , 109, 1081-1091		2
28	A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes. 2021 , 13,		0
27	End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 529-542	4.5	4
26	Regulatory Requirements and Comparison of Approval of New and Generic Drugs in the United States of America and Japan: Implication for Future Strategies. 2021 , 8, 32-47		1
25	Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments. 2021 , 23, 63		1
24	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. 2021 , 61 Suppl 1, S52-S59		0
23	Pharmacokinetic Modeling and Predictive Performance: Practical Considerations for Therapeutic Monoclonal Antibodies. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 46, 595-600	2.7	0
22	An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1961-1972	2.5	1
21	Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood Flow. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
20	Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis. <i>Antibiotics</i> , 2021 , 10,	4.9	0
19	Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice. <i>Arhiv Za Farmaciju</i> , 2021 , 71, 336-353	0.2	
18	Pharmacometrics Applications to Pediatric Trials. 332-341		1
17	Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 914-921	2.3	3

16	Pharmacometrics in Pulmonary Diseases. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 349-382	3.2	1
15	Pharmacometrics in Cardiovascular Safety. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 189-227	0.5	3
14	Pharmacometrics: A Quantitative Decision-Making Tool in Drug Development. 2020 , 71-104		2
13	Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e66	4.5	3
12	Clinical Trial Simulation. 2014 , 239-271		
11	[The Current State and Future Prospects of Population Pharmacokinetic Research in Post-marketing Clinical Studies in Japan]. <i>Yakugaku Zasshi</i> , 2019 , 139, 1297-1303	0	1
10	External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
9	The clinical population pharmacokinetics, metabolomics and therapeutic analysis of alkaloids from <i>Alstonia scholaris</i> leaves in acute bronchitis patients.. <i>Phytomedicine</i> , 2022 , 98, 153979	6.5	0
8	Table_1.docx. 2020 ,		
7	Table_2.docx. 2020 ,		
6	Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.. <i>Pharmaceutical Research</i> , 2022 ,	4.5	1
5	Pharmacometrics: Definition and History. 2022 , 933-939		
4	Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients. 2022 , 14, 1920		0
3	A Survey of Population Pharmacokinetic Reports Submitted to the USFDA: An Analysis of Common Issues in NDA and BLA from 2012 to 2021.		0
2	A pharmacokinetic model of antiseizure medication load to guide care in the epilepsy monitoring unit.		0
1	Pharmacometrics: A New Era of Pharmacotherapy and Drug Development in Low- and Middle-Income Countries. 2023 , 2023, 1-10		0